Subcapsular hematoma after laparoscopic cholecystectomy, associated with ketorolac administration

Research output: Contribution to journalArticle

20 Citations (Scopus)

Abstract

Ketorolac is the first injectable nonsteroidal antiinflammatory drug used as an analgesic in the perioperative period. Its adverse effect profile is different from that of the opioid analgesics; in particular, in its lack of respiratory depressive actions. However, ketorolac has risks associated with its perioperative administration, including episodes of substantial gastrointestinal bleeding. A patient undergoing elective laparoscopic cholecystectomy developed a subcapsular hepatic hematoma shortly after receiving a dose of injectable ketorolac. No evidence of parenchymal injury was found on laparoscopy, which argues against iatrogenic trauma. Clinicians should be aware that ketorolac may cause or aggravate bleeding, and it should be used with caution in perioperative patients.

Original languageEnglish (US)
Pages (from-to)613-615
Number of pages3
JournalPharmacotherapy
Volume14
Issue number5
StatePublished - 1994

Fingerprint

Ketorolac
Laparoscopic Cholecystectomy
Hematoma
Hemorrhage
Perioperative Period
Injections
Wounds and Injuries
Laparoscopy
Opioid Analgesics
Analgesics
Anti-Inflammatory Agents
Liver
Pharmaceutical Preparations

ASJC Scopus subject areas

  • Pharmacology (medical)
  • Pharmacology, Toxicology and Pharmaceutics(all)

Cite this

@article{037aeec3c0374d3f8e1990b878ce4fbf,
title = "Subcapsular hematoma after laparoscopic cholecystectomy, associated with ketorolac administration",
abstract = "Ketorolac is the first injectable nonsteroidal antiinflammatory drug used as an analgesic in the perioperative period. Its adverse effect profile is different from that of the opioid analgesics; in particular, in its lack of respiratory depressive actions. However, ketorolac has risks associated with its perioperative administration, including episodes of substantial gastrointestinal bleeding. A patient undergoing elective laparoscopic cholecystectomy developed a subcapsular hepatic hematoma shortly after receiving a dose of injectable ketorolac. No evidence of parenchymal injury was found on laparoscopy, which argues against iatrogenic trauma. Clinicians should be aware that ketorolac may cause or aggravate bleeding, and it should be used with caution in perioperative patients.",
author = "Erstad, {Brian L} and Adamas-Rappaport, {William -}",
year = "1994",
language = "English (US)",
volume = "14",
pages = "613--615",
journal = "Pharmacotherapy",
issn = "0277-0008",
publisher = "Pharmacotherapy Publications Inc.",
number = "5",

}

TY - JOUR

T1 - Subcapsular hematoma after laparoscopic cholecystectomy, associated with ketorolac administration

AU - Erstad, Brian L

AU - Adamas-Rappaport, William -

PY - 1994

Y1 - 1994

N2 - Ketorolac is the first injectable nonsteroidal antiinflammatory drug used as an analgesic in the perioperative period. Its adverse effect profile is different from that of the opioid analgesics; in particular, in its lack of respiratory depressive actions. However, ketorolac has risks associated with its perioperative administration, including episodes of substantial gastrointestinal bleeding. A patient undergoing elective laparoscopic cholecystectomy developed a subcapsular hepatic hematoma shortly after receiving a dose of injectable ketorolac. No evidence of parenchymal injury was found on laparoscopy, which argues against iatrogenic trauma. Clinicians should be aware that ketorolac may cause or aggravate bleeding, and it should be used with caution in perioperative patients.

AB - Ketorolac is the first injectable nonsteroidal antiinflammatory drug used as an analgesic in the perioperative period. Its adverse effect profile is different from that of the opioid analgesics; in particular, in its lack of respiratory depressive actions. However, ketorolac has risks associated with its perioperative administration, including episodes of substantial gastrointestinal bleeding. A patient undergoing elective laparoscopic cholecystectomy developed a subcapsular hepatic hematoma shortly after receiving a dose of injectable ketorolac. No evidence of parenchymal injury was found on laparoscopy, which argues against iatrogenic trauma. Clinicians should be aware that ketorolac may cause or aggravate bleeding, and it should be used with caution in perioperative patients.

UR - http://www.scopus.com/inward/record.url?scp=0027997196&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0027997196&partnerID=8YFLogxK

M3 - Article

C2 - 7997396

AN - SCOPUS:0027997196

VL - 14

SP - 613

EP - 615

JO - Pharmacotherapy

JF - Pharmacotherapy

SN - 0277-0008

IS - 5

ER -